跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

N-059

Supelco

降丙吗啡标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C25H35NO4
CAS号:
78715-23-8
分子量:
413.55
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

certified reference material

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

濃度

1.0 mg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

forensics and toxicology

形式

single component solution

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4)c56

InChI

1S/C25H35NO4/c1-21(2,3)22(4,28)16-13-23-8-9-25(16,29-5)20-24(23)10-11-26-17(23)12-14-6-7-15(27)19(30-20)18(14)24/h6-7,16-17,20,26-28H,8-13H2,1-5H3/t16-,17-,20-,22+,23-,24+,25-/m1/s1

InChI 密鑰

YOYLLRBMGQRFTN-IOMBULRVSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

A new Certified Spiking Solution® suitable for use in clinical toxicology, forensic testing, or pain prescription monitoring.

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

相關產品

产品编号
说明
价格

B-035

丁丙诺啡葡糖苷酸标准液 溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-044

丁丙诺啡标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-901

丁丙诺啡-D4 溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-902

丁丙诺啡标准液 溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-908

丁丙诺啡-D4 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-071

13种疼痛管理混标 溶液, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

N-045

Norbuprenorphine glucuronide solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-912

降丙吗啡标准液 溶液, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-920

Norbuprenorphine-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-921

Norbuprenorphine-D3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-100

Buprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-101

Buprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-145

Norbuprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-146

Norbuprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-059S

降丙吗啡标准液 溶液, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 1

閃點（°F）

49.5 °F - closed cup

閃點（°C）

9.7 °C - closed cup

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Marta Concheiro et al.
Therapeutic drug monitoring, 33(5), 619-626 (2011-08-24)
Buprenorphine is currently under investigation as a pharmacotherapy to treat pregnant women for opioid dependence. This research evaluates buprenorphine (BUP), norbuprenophine (NBUP), buprenorphine-glucuronide (BUP-Gluc), and norbuprenorphine-glucuronide (NBUP-Gluc) pharmacokinetics after high-dose (14-20 mg) BUP sublingual tablet administration in three opioid-dependent pregnant
Hong K Kim et al.
Pediatrics, 130(6), e1700-e1703 (2012-11-07)
Buprenorphine is a partial μ-opioid receptor agonist that is approved for the treatment of opioid dependency. It is generally believed to be safer than methadone because of its ceiling effect on respiratory depression. As more adults in US households use
Giuseppe Lippi et al.
Journal of clinical laboratory analysis, 25(4), 244-245 (2011-07-26)
Buprenorphine is a centrally acting analgesic drug that is administered for the management of opioid dependence and as an analgesic drug for the treatment of chronic pain. The growing use of this substance has determined an increased need for laboratory
Tor Seldén et al.
Forensic science international, 220(1-3), 284-290 (2012-05-09)
Buprenorphine is considered to have little respiratory side effects at therapeutic doses and the partial agonistic properties should produce a "ceiling effect" for respiratory depression at higher doses. Still, there are several reports on buprenorphine related deaths. Most deaths involve
Kenneth F Ilett et al.
Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine, 7, 269-274 (2011-10-21)
The aim of the present study was to estimate the dose of buprenorphine and its primary metabolite norbuprenorphine that a breastfed infant would receive during maternal maintenance treatment with buprenorphine. Seven pregnant opioid-dependent women taking buprenorphine (median, 7 mg/day; range, 2.4-24 mg)
查看所有相关文献

实验方案

LC/MS (TOF) Analysis of Drugs and Their Glucuronide Metabolites in Urine on Titan™ C18 after Solid Phase Extraction (SPE) using Supel™-Select SCX, β-Glucuronidase Enzyme Digestion

-THC solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

Using UHPLC/MS (TOF) for Detection of Drugs and Metabolites in Urine Following Optimized Enzymatic Hydrolysis Conditions

To optimize hydrolysis using β-glucuronidase, factors such as incubation time, temperature, hydrolysis pH, enzyme source, and enzyme concentration must be evaluated for each glucuronide metabolite to be analyzed.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门